🇺🇸 FDA
Pipeline program

Ex-vivo expanded allogeneic γδT cells

IIT2020028-EC-3

Phase 1 mab active

Quick answer

Ex-vivo expanded allogeneic γδT cells for Non-Hodgkin's Lymphoma (NHL) is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Non-Hodgkin's Lymphoma (NHL)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials